MedTrace Logo

Effect of Collavant® n2 in Healthy Male Adults With Exercise-induced Joint Discomfort.

NCT07561203 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-05-13

No results posted yet for this study

Summary

The present clinical study has been designed to evaluate the effect of Collavant® n2 at a daily dose of 40 mg on joint function and performance in healthy, amateur male runners with exercise-induced knee discomfort.

Conditions

  • Healthy Adult Male

Interventions

DIETARY_SUPPLEMENT

Native type II collagen (Collavant® n2)

Native type II collagen (Collavant® n2). 1 capsule 40 mg / day

OTHER

Placebo

Placebo. 1 capsule / day

Sponsors & Collaborators

  • Universidad Politecnica de Madrid

    collaborator OTHER

  • Bioiberica

    lead INDUSTRY

Principal Investigators

  • Marcela González-Gross, Professor · Universidad Politecnica de Madrid

  • Javier Modrego-Martin, Doctor · Universidad Politecnica de Madrid

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-06
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07561203 on ClinicalTrials.gov